Member Info for Paul2566

Well it would appear another fund raise is looming a little sooner than I anticipated.
If its another share issue aimed at private investors, I don't think it will work, I can't see the volume being taken up in sufficient quantities at this time, not with the information currently available.
I don't think the BOD are idiots and they will have considered this. I can only think that they believe there is some news to be released in the next 6 weeks that will change investor sentiment.
Its not unusual for fledgling companies to need to raise additional capital, so should come as no surprise to investors, but timing is everything, and something will be needed to positively impact sentiment in this stock.
Its unusual for MXC to be so quiet, Roby does like to tweet, and he has been quiet since 20th Dec.
I think something is coming, I'm just not sure if its going to be positive or negative news.

Trek
Shame more don't post in a similar vein.

I don't dissagree that MXC has some red flags, thats what makes it such a high risk speculative share, but from someone who purports to be some sort of expert I would expect some meat on the bone of that statement.
As to valuation, I'm no expert, but have tried to value MXC with little success, as is often the way with a loss making company trading on potential in a competitive pharma market.
I was unaware of the limit rule on shorts, well every day is a school day.
I'm still not convinced that MXC is being shorted however, purely because there is no great interest from institutional investors in this stock.
Its unusual for institutional investors to hold stock of companies that are very risky, thinly traded, or very small, and MXC is all three.
From memory I think there was one, maybe two IIs who held a small amount of stock, but not sure if they still do.

Posts crossed Gazzleberry, I'm such a slow typer.

There is also another piece from Tom Winnifrith on MXC, posted on '*************'.
I must say its poor writing at best with little content, I don't see why an RNS should be a red flag. There is a lawful obligation to release an RNS by any listed company under circumstance that the news may effect the stocks price.
He goes on to state the company is 'drowning in red flags' but doesn't expand on this statement.
He also states the valuation is absurd, but again gives no rational as to why.
I must agree with you Gazzleberry, he comes over as a bit of a buffoon.

Gazzleberry
Thanks, for a moment I thought you meant Terry Wood.
There don't appear to be any short positions open on MXC at the moment, or in the past 6 months.
The piece by Tom Winnifrith appears to be aimed (pun intended) at MXC Capital (ticker MXCP) which is listed on AIM and possibly confused with MGC Pharma (ticker MXC) listed on the main markets.

For me its April 6th, when I will make the decision to stick with this or move the investment elsewhere.
Good news is that the bottom appears to be around 2p, so the upside is probably greater than the downside.
Bad news is that there is practically no dealing volume, which would indicate a considerable lack of interest, even the 'nickle and dime' trades have dropped.
I am expecting interim results to be published towards the end of February, which hopefully will provide some clarity to the financial outlook of MXC. I suspect it will show another increase in income over the previous period, increased costs and not yet at break even. It should indicate if a further fund raise is likely in the near term, and if a further dilution of investor holdings is the likely result, and will do little to increase positive investor sentiment.
The results of the study into the efficacy of ArtemiC Support® as a treatment for Long COVID is also due in February.
I feel the time for this stock moving on positive 'jam tomorrow' news has past, and the only thing likely to invigorate investors is an improvement in the balance sheet that outperforms expectations.
Even Roby seems to have gone quiet, is this the run up to some breakthrough news or is there just nothing positive to report.
In any event February is likely to be an important month, one way or another.

This is very criptic. What/who is TW, and why do you mention them ?

I've only held VOD for 14 months, so not long in the scheme of things.
I bought it for the dividend, so if things stay the same I will break even in another 2 dividends. I just made a minor mistake and with hindsight (what a wonderful thing that is) bought at the wrong time. I don't like seeing red on the portfolio, but it means little unless I close. As long as the dividend keeps rolling in to re-invest I'll not worry too much. I have other stocks for growth.
I could have averaged down, but that would overweight my portfolio in respect of VOD, and through personal choice and my comfortable risk, I wasn't prepaired to do that. Experience and history has shown me that any stock can be subjected to a 'black swan'.
If I was unhappy with VOD, I'd take the small hit and move the funds elsewhere.

I of course also hold GLO which at the current SP is about 4.6% of my portfolio.

Sam
I'm not saying now is the best time to buy, or even that they will suit your risk levels, and I do hold all the stocks I'm about to mention, so may be biased. They have been good to me not only for the dividends but I just got plain lucky when I bought the stock, so the dividend returns in relation to my investment is generally better, if that makes sense.
LGEN, ADM, DLG, RIO, PHNX, AV., and BP.
I have no intention of selling any of the above stocks unless of course their long term financials take a turn for the worse of course.
Together they represent about 45% of my portfolio.

Magstar
While I must admit talk of a 20% rise is a bit optimistic to say the least, a rise of 1% to 2% would be realistic.
What will make a difference is if any notable increase in sales leads to the company reaching break even earlier than expected.
CimetrA is the product that if its adopted as a result of any positive light being shone on MXC, would be a nice outcome, and I suspect lead to the company turning a small profit for the first time.
Its if/when MCX becomes self funding that we will see sentiment improve long term.
This news is none the less a small step in the right direction, and may result in other countries following suit.

Any notable rise in the SP while welcome is not the main reason for a brighter outlook. Any worthwhile increase in sales will hopefully allow accelerated development of their other pipeline products, and better marketing. MXC have what appears to be some very worthwhile products in development, which if brought to market will really get things moving.

Well I didn't believe this would happen.
To use a product from a non-core pharma company in a time of national emergency is politically a very bold move, and I just didn't think any politician would have the guts or foresight to make such a move. If it attracted bad press for any reason its political suicide.
However if it goes well in India, other politicians in other countries will be more likely to take similar actions, as there will be less political risk.
Its something our politicians would never have done, but they may be happy to follow suit.
Sometimes its nice to be so wrong, and perhaps I shouldn't view all gouvernments in the same light as ours.

I've said it before, forget covid, that train left a while ago. MXC does not produce any cures for this virus, it produces treatments for the conditions resulting from it.
There will be no contracts in the UK India or elsewhere for that matter.
MXC has many products in testing and in the pipeline that could be used to treat other conditions, that is where their future lies. That going to take a couple of years to bear fruit.
Tey have made no suggestion that they will get into the 'recreartonal market', and thats a good decision, you won't find Astra, GSK etc. doing this either.
If you are looking for a short term win with MXC, look elsewhere, over the medium to long term it may be a much more profitable investment.
Most posters have done little research which is evident in their posts.
This is and remains a high risk speculative investment which should be entered into with a 5 to 10 year horizon, and in the knowledge that it could not only make a reasonable return, but could also fain completly in equal measure.
I'm currently down 30% or about £4500 on this stock and still holding as although dissapointing isn't really much of a surprise.
I still see 3p within the next 18 months as a possibility, but until they bring more products to market its going to stay around 2p +/- 15%.
If they fail to bring products to market in any meaningful volume in the next 12 months expect to see 1.5p.
Is it worth buying, well that depends on your circumstances. If it only represents less than 5% of your portfolio, then it may be worth the gamble (as that is what it is at the moment). High risk and potentially high reward. If you intend to put 25% of your portfolios value in this, then its madness.
MXC appears to have done some good foundation work over the last couple of years, and it still could pay off nicely, but not anytime soon.
If an investor isn't prepared to hold this at least for the medium term, they are most likely going to be very dissapointed.

If MXC proves to be a success, its unlikly there would be any surplus of their cannabis plants to sell on.
Their 'High THC' products are still pharma products, not designed for recreational use, and the legislation mentioned will not change the need for a prescription. The news event posted is unreleated to MXC, and is unlikly to have any impact on MXC.
I don't think its likly MXC will stray into the recreational use market. All their work so far has been building a reputaion for natural pharma products, dabbling with recreational use would do little to help this.
It might be worth researching those products in testion, and pipeline to understand something of the stock.

News relates to substances high in THC, i.e. recreational use.
MXC is a pharma company so not sure why it should prompt the investment, as a totally different market.

Just as long as we don't have a repeat of the early 90s. I'm sure some on here will remember the eye watering mortgage rates and negative equity.

Guessing this mornings rise is due to the change in the markets view of Omicron.

I'm a little under water with this at the moment. I will probably hold at least till April, then reasses in my annual balance of stocks. I will most likly hold the VOD held in the ISA, but the bed VOD stock may get sold and allocated elsewhere.